--- title: "U.S. stock market midday update: Instinct Bio down 63.61%, no major negative news, capital movement draws attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/293944159.md" description: "Instinct Bio Technical fell 63.61%; Forte Biosciences rose 39.52%, with a transaction volume of USD 617 million; AbbVie rose 0.66%, with a transaction volume of USD 103 million; Fortis Pharmaceuticals rose 1.73%, with a transaction volume of USD 8.565 million; Amgen rose 0.97%, with a market value of USD 204.8 billion" datetime: "2026-07-27T13:58:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293944159.md) - [en](https://longbridge.com/en/news/293944159.md) - [zh-HK](https://longbridge.com/zh-HK/news/293944159.md) generator: "portal-rs" --- # U.S. stock market midday update: Instinct Bio down 63.61%, no major negative news, capital movement draws attention **U.S. Stock Market Midday Update** Instinct Bio Technical, down 63.61%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Forte Biosciences up 39.52%. Based on recent key news: 1. On July 27, Forte Biosciences agreed to be acquired by the Belgium-Netherlands immunology company argenx for $2.2 billion. The deal is conducted at $77 per share in cash, a premium of about 41% over last Friday's closing price, driving the stock price up. Source: WSJ 2. On July 27, after the acquisition of Forte Biosciences, argenx will gain its main project FB102, which has shown early potential in treating vitiligo and celiac disease, expanding its immunology product portfolio. Source: AASTOCKS 3. On July 27, analysts believe FB102 has the potential to become a blockbuster drug for treating vitiligo and celiac disease, and the acquisition aligns with argenx's core strategy. Source: J.P. Morgan. The immunology sector is active in acquisitions, with attention to risks. AbbVie up 0.66%. Based on recent key news: 1. On July 23, AbbVie and Genmab clarified that the primary endpoint of the EPCORE DLBCL-1 trial did not meet expectations, leading to market concerns about its R&D prospects, causing stock price fluctuations. 2. On July 24, AbbVie announced it will release its second-quarter financial report on July 31, expecting revenue of $16.79 billion and earnings per share of $3.60, with high market expectations driving the stock price up. 3. On July 25, analysts pointed out that AbbVie has a 2.7% attractive dividend yield and a robust pharmaceutical business, maintaining investor confidence in its long-term performance, leading to a rise in stock price. The pharmaceutical industry has shown steady performance recently, with significant capital inflow. Forte Pharmaceuticals up 1.73%. Based on recent key news: 1. On July 24, Vertex Pharmaceuticals received FDA approval for its CRISPR gene-editing therapy for young children, boosting the biotechnology sector. This event enhanced market confidence in biotechnology innovation, benefiting Forte Pharmaceuticals, which saw its stock price rise by 1.73%. Source: MarketBeat 2. On July 24, Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics, expanding its influence in the endocrine disease field. This move is seen as a strategic expansion, raising market expectations for related companies, positively impacting Forte Pharmaceuticals' stock price. Source: MarketBeat On July 25, analysts rated Vertex Pharmaceuticals as a moderate buy, but believe that five other stocks are more attractive. Nevertheless, Fortrea Pharmaceuticals continues to benefit from positive sentiment in the biotechnology sector. Source: MarketBeat The biotechnology sector has recently performed strongly, with significant capital inflows. **Stocks Ranked Among the Top by Market Capitalization in the Industry** Amgen rose by 0.97%. Based on recent news, 1. On July 24, Amgen submitted data to the FDA, seeking a hearing to respond to the proposal for withdrawal. Amgen strongly opposes the FDA's proposal to withdraw the sale of Tavneos in the U.S. market, leading to a rise in stock prices. 2. On July 24, the FDA confirmed 76 cases of severe liver injury associated with Tavneos, including 8 deaths and 7 cases of rare conditions. Nevertheless, the FDA stated that Tavneos will continue to be sold in the U.S. market unless Amgen voluntarily withdraws or the FDA commissioner orders a withdrawal. 3. On July 24, the European Medicines Agency recommended the withdrawal of Tavneos' approval, citing unreliable research data. Nevertheless, Amgen's drugs like Repatha received a label extension recommendation from the CHMP, boosting market confidence. The pharmaceutical industry has been quite volatile recently, and policy changes should be closely monitored ### Related Stocks - [BIOT.US](https://longbridge.com/en/quote/BIOT.US.md) - [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Instinct Bio partners with Indonesia’s Parva Candela to expand cosmetics business](https://longbridge.com/en/news/295396196.md) - [Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth | ACQC Stock News](https://longbridge.com/en/news/294079569.md) - [Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT](https://longbridge.com/en/news/294161543.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**